Abstract
Raynaud phenomenon is a symptom complex caused by impaired digital perfusion and can occur as a primary phenomenon or secondary to a wide range of underlying causes. Raynaud phenomenon occurs in virtually all patients with systemic sclerosis (SSc) and is often the earliest clinical manifestation to occur. Careful assessment is required in patients with Raynaud phenomenon to avoid missing secondary causes such as SSc. Digital ulcers are a painful and disabling visible manifestation of digital vascular injury in patients with SSc. Progress has been made in the classification and assessment of digital ulcers and in understanding ulcer pathogenesis, and there are a wide range of treatments available to both prevent and heal digital ulcers, some of which are also used in Raynaud phenomenon management. In this Review, the assessment of patients with Raynaud phenomenon is discussed, including ‘red flags’ that are suggestive of SSc. The pathogenesis, classification and assessment of SSc-associated digital ulcers are also covered, alongside an overview of management approaches for SSc-associated Raynaud phenomenon and digital ulcers. Finally, unmet needs are discussed and the concept of a unified vascular phenotype in which therapies that affect the vasculature to support disease modification strategies is introduced.
Original language | English |
---|---|
Pages (from-to) | 208-221 |
Number of pages | 14 |
Journal | Nature Reviews Rheumatology |
Volume | 16 |
Issue number | 4 |
Early online date | 25 Feb 2020 |
DOIs | |
Publication status | Published - 30 Apr 2020 |
Funding
M.H. declares he has received speaker honoraria from Actelion. Y.A. declares he has or has had a consultancy relationship and/or has received grants from Actelion, Bayer, BMS, Boehringer-Ingelheim, Inventiva, Roche, Sanofi-Aventis and Servier in the area of systemic sclerosis. L.C. declares she has consultancy or advisory relationships with BMS, Boehringer-Ingelheim, Eicos, Mitsubishi Tanabe and Reata. J.D.P. declares he has received speaker honoraria and research grant support from Actelion and has undertaken consultancy work for Actelion and Boehringer-Ingelheim. C.P.D. declares he has received research grants from CSL Behring, GlaxoSmithKline and Inventiva and consulting fees from Actelion, Bayer, Boehringer-Ingelheim, CSL Behring, Galapagos, GlaxoSmithKline, Inventiva, Leadiant, Roche and Sanofi. M.M.-C. declares he has received speaker honoraria from Actelion and Biogen.
Keywords
- Fingers/blood supply
- Humans
- Raynaud Disease/complications
- Scleroderma, Systemic/complications
- Skin Ulcer/diagnosis